When fully automated waste and recycling facilities were just a concept in the industry, Norwegian municipal solid waste (MSW) hauling company Romerike Avfallsforedling (RoAF) turned the concept into a reality.
Powered by a sorting system installed by Germany-based Stadler Anlagenbau GmbH, RoAF opened the world’s first fully automated mixed waste processing facility in 2016 in the village of Skedsmokorset, just outside of Oslo, to help meet the needs of Norwegian municipalities that were facing high labor costs. While the concept was three years in the making, Stadler needed just three months to complete construction of the facility.
RoAF collects household and food waste from 10 municipalities in Norway, including Skedsmo, which boasts a population of roughly 53,000 people. When waste arrives at the automated plant, it’s first fed onto a conveyor, which delivers the waste into the sorting plant.
Fully automated autonomous city face_with_colon_three
Final Thoughts
The photos above are intended to open your mind to the possibilities of living in a 24-hour city.
There are many side effects to automation and not all of them are positive. But one aspect of our automated future will be 24-hour access to most goods and services, many of which are only available during normal business hours today.
Lower handgrip strength is associated with higher 2-year death risk in older heart failure patients, with stronger impact at advanced ages. @NakadeTaisuke@yuya_matsue
Glia previously thought to be support cells of brain but recent evidence suggest that the astrocytes, the most abundant glial cell type in addition to supplying neurons with lactate via glycolysis also actively engage in lipid metabolism, especially mitochondrial fatty acid β-oxidation.
Researchers in this review integrate astrocytic fatty acid ß-oxidation and ketogenesis, alongside other metabolic pathways converging on reactive oxygen species dynamics, including cholesterol metabolism and peroxisomal β-oxidation.
Astrocytes, the most abundant glial cell type in the central nervous system, have traditionally been viewed from the perspective of metabolic support, particularly supplying neurons with lactate via glycolysis. This view has focused heavily on glucose metabolism as the primary mode of sustaining neuronal function. However, recent research challenges this paradigm by positioning astrocytes as dynamic metabolic hubs that actively engage in lipid metabolism, especially mitochondrial fatty acid β-oxidation. Far from serving solely as an energy source, fatty acid ß-oxidation in astrocytes orchestrates reactive oxygen species-mediated signaling pathways that modulate neuron-glia communication and cognitive outcomes.
Live from CES in Las Vegas, NVIDIA CEO Jensen Huang shares how the next generation of accelerated computing and AI will transform every industry. The event kicks off with a one-hour NVIDIA pregame show where panelists discuss the future of AI infrastructure, open ecosystems, and physical AI.
The first NMNH human trial shows NAD+ levels increased up to 3x in 90 days. Here’s what the data actually reveal—and what’s still missing. Some links are affiliate links so we will earn a commission when they are used to purchase products.
The first human clinical trial results for NMNH are here. In this 90-day randomized, double-blind, placebo-controlled study, NMNH increased NAD+ levels up to 3x in healthy adults, with participants reporting improvements in energy and fatigue. But before you get too excited, there are important limitations to understand. In this video, I break down the trial design, explain what the NAD+ increases actually mean, review the subjective outcomes like energy and emotional well-being (measured via SF-36), and discuss why the biological age claims are difficult to interpret. I also cover safety data and what we still need to know. This is promising early data for NMNH vs NMN, but it’s unpublished, lacks key details, and needs independent replication. Here’s everything you need to know about what this trial does and doesn’t tell us. Key topics: NMNH clinical trial, NAD+ boosters, NMN vs NMNH, longevity supplements, anti-aging research, NAD+ levels, UthPeak study, Phase I trial results.
📚 Chapters. 0:00 — Introduction & Trial Overview What this video covers and the trial basics. 1:39 — Trial Design & Methodology Study structure, participants, and objectives. 2:31 — NAD+ Results The primary outcome: dose-dependent increases. 3:18 — Subjective Outcomes & Limitations Energy, mood, biological age claims, and why interpretation is difficult. 6:26 — Safety & Final Thoughts Tolerability data and what comes next.
🌐Links in this video. NMNH Clinical Trial https://www.clinicaltrials.gov/study/.… nicotinamide mononucleotide is a new and potent NAD+ precursor in mammalian cells and mice https://faseb.onlinelibrary.wiley.com… Reduced Nicotinamide Mononucleotide (NMNH) Potently Enhances NAD+ and Suppresses Glycolysis, the TCA Cycle, and Cell Growth https://pubmed.ncbi.nlm.nih.gov/33793… *************************************** Health claims Disclosure: Information provided on this video is not a substitute for direct, individual medical treatment or advice. Please consult with your doctor first. Products or services mentioned in this video are not a recommendation. Audio Copyright Disclaimer Please note that we have full authorization to the music that we used in our videos as they were created using the service WeVideo which provides the rights to the music. The rights are detailed in the terms of use that can be reviewed here https://www.wevideo.com/terms-of-use and any following inquiries should be addressed to [email protected]. ********************************************** #nmnh #nad #nmn. Reduced nicotinamide mononucleotide is a new and potent NAD+ precursor in mammalian cells and mice. https://faseb.onlinelibrary.wiley.com… Reduced Nicotinamide Mononucleotide (NMNH) Potently Enhances NAD+ and Suppresses Glycolysis, the TCA Cycle, and Cell Growth. https://pubmed.ncbi.nlm.nih.gov/33793…
Aging or injury to the joints can lead to cartilage degeneration and osteoarthritis (OA), for which there are limited effective treatments. We found that expression of 15-hydroxy prostaglandin dehydrogenase (15-PGDH) is increased in the articular cartilage of aged or injured mice. Both systemic and local inhibition of 15-PGDH with a small molecule inhibitor (PGDHi) led to regeneration of articular cartilage and reduction in OA-associated pain. Using single cell RNA-sequencing and multiplexed immunofluorescence imaging of cartilage, we identified the major chondrocyte subpopulations. Inhibition of 15-PGDH decreased hypertrophic-like chondrocytes expressing 15-PGDH and increased extracellular matrix-synthesizing articular chondrocytes. Cartilage regeneration appears to occur through gene expression changes in pre-existing chondrocytes, rather than stem or progenitor cell proliferation.
A rebrand for proteasome inhibition in solid tumors.
In this Research Letter, Jonathan M. Hernandez & team investigate the potential of hepatic artery infusion pump delivery of carfilzomib, to continuously direct a large dose to the tumor with least hepatic toxicity.
Address correspondence to: Jonathan M. Hernandez, National Cancer Institute, NIH, 10 Center Drive, Room 4W-3752, Bethesda, Maryland, 20,892, USA. Email: Jonathan. [email protected].
